Literature DB >> 24816902

The effect of quitting smoking on costs and healthcare utilization in patients with chronic obstructive pulmonary disease: a comparison of current smokers versus ex-smokers in routine clinical practice.

Antoni Sicras-Mainar1, Javier Rejas-Gutiérrez, Ruth Navarro-Artieda, Jordi Ibáñez-Nolla.   

Abstract

PURPOSE: Chronic obstructive pulmonary disease (COPD) is a prevalent condition mainly related to smoking, which is associated with a substantial economic burden. The purpose was to compare healthcare resource utilization and costs according to smoking status in patients with COPD in routine clinical practice.
METHODS: A retrospective cohort nested case-control study was designed. The cohort was composed of male and female COPD outpatients, 40 years or older, covered by the Badalona Serveis Assistencials (a health provider) health plan. Cases were current smokers with COPD and controls (two per case) were former smokers with COPD (at least 12 months without smoking), matched for age, sex, duration of COPD, and burden of comorbidity. The index date was the last visit recorded in the database, and the analysis was performed retrospectively on healthcare resource utilization data for the 12 months before the index date.
RESULTS: A total of 930 COPD records were analyzed: 310 current and 620 former smokers [mean age 69.4 years (84.6 % male)]. Cases had more exacerbations, physician visits of any type, and drug therapies related to COPD were more common. As a consequence, current smokers had higher average annual healthcare costs: €3,784 (1,888) versus €2,302 (2,451), p < 0.001. This difference persisted after adjusting for severity of COPD.
CONCLUSIONS: Current smokers with COPD had significantly higher use of healthcare resources, mainly COPD drugs and physician visits, compared with former smokers who had abstained for at least 12 months. As a consequence, current smokers had higher healthcare costs to the National Health System in Spain than ex-smokers.

Entities:  

Mesh:

Year:  2014        PMID: 24816902     DOI: 10.1007/s00408-014-9592-7

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  45 in total

1.  Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score.

Authors:  Catherine McGorrian; Salim Yusuf; Shofiqul Islam; Hyejung Jung; Sumathy Rangarajan; Alvaro Avezum; Dorairaj Prabhakaran; Wael Almahmeed; Zvonko Rumboldt; Andrzej Budaj; Antonio L Dans; Hertzel C Gerstein; Koon Teo; Sonia S Anand
Journal:  Eur Heart J       Date:  2010-12-22       Impact factor: 29.983

2.  Defining COPD exacerbations: impact on estimation of incidence and burden in primary care.

Authors:  John F O'Reilly; Angela E Williams; Kay Holt; Leanne Rice
Journal:  Prim Care Respir J       Date:  2006-10-24

3.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

4.  Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD).

Authors:  José Luis Izquierdo-Alonso; Jose Miguel Rodriguez-Gonzálezmoro; Pilar de Lucas-Ramos; Irune Unzueta; Xabier Ribera; Esther Antón; Antonio Martín
Journal:  Respir Med       Date:  2013-02-16       Impact factor: 3.415

Review 5.  Clinical phenotypes of COPD: identification, definition and implications for guidelines.

Authors:  Marc Miravitlles; Myriam Calle; Juan José Soler-Cataluña
Journal:  Arch Bronconeumol       Date:  2011-12-22       Impact factor: 4.872

Review 6.  Co-morbidities in people with COPD: a result of multiple diseases, or multiple manifestations of smoking and reactive inflammation?

Authors:  Barbara P Yawn; Alan Kaplan
Journal:  Prim Care Respir J       Date:  2008-12

7.  Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort.

Authors:  Lisa Langsetmo; Robert W Platt; Pierre Ernst; Jean Bourbeau
Journal:  Am J Respir Crit Care Med       Date:  2007-11-29       Impact factor: 21.405

Review 8.  The economic impact of acute exacerbations of chronic bronchitis in the United States and Canada: a literature review.

Authors:  Michael T Halpern; Mitchell K Higashi; Alan W Bakst; Jordana K Schmier
Journal:  J Manag Care Pharm       Date:  2003 Jul-Aug

Review 9.  Cost-effectiveness of smoking cessation and the implications for COPD.

Authors:  Michele A Faulkner; Tom L Lenz; Julie A Stading
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 10.  Beyond FEV₁ in COPD: a review of patient-reported outcomes and their measurement.

Authors:  Paul Jones; Marc Miravitlles; Thys van der Molen; Karoly Kulich
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-10-16
View more
  3 in total

1.  Healthcare Costs of Smokers Using Varenicline Versus Nicotine-Replacement Therapy Patch in the United States: Evidence from Real-World Practice.

Authors:  Lauren J Lee; Qian Li; Marianna Bruno; Birol Emir; Brian Murphy; Surbhi Shah; Matthew Reynolds; Nick Marchant; Peter W Park
Journal:  Adv Ther       Date:  2018-12-19       Impact factor: 3.845

2.  Clinical and Economic Consequences of Inhaled Corticosteroid Doses and Particle Size in Triple Inhalation Therapy for COPD: Real-Life Study.

Authors:  Antoni Sicras-Mainar; Francisco J de Abajo; José Luis Izquierdo-Alonso
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-12-09

3.  Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain.

Authors:  Carlos A Jiménez-Ruiz; Segismundo Solano-Reina; Jaime Signes-Costa; Eva de Higes-Martinez; José I Granda-Orive; José J Lorza-Blasco; Juan A Riesco-Miranda; Neus Altet-Gomez; Miguel Barrueco; Itziar Oyagüez; Javier Rejas
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-09-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.